CMS will allow clinicians who participate in the Quality Payment Program to earn credit in the Merit-based Incentive Payment System (MIPS) for participation in a coronavirus disease 2019 (COVID-19) clinical trial and reporting clinical information; President Trump announced via Twitter that he would sign an executive order to temporarily suspend immigration; findings from antibody testing in Los Angeles indicate that more people have been infected with COVID-19 than initially confirmed.
CMS will allow clinicians who participate in the Quality Payment Program to earn credit in the Merit-based Incentive Payment System (MIPS) for participation in a coronavirus disease 2019 (COVID-19) clinical trial and reporting clinical information. CMS said the move will help improve patient care. Clinicians must attest that they participate in a COVID-19 clinical trial using a drug or biological product to treat a patient with a COVID-19 infection and report their findings through a clinical data repository or clinical data registry for the duration of their study.
President Trump said in a tweet yesterday that he will be signing an executive order “to temporarily suspend immigration into the United States,” claiming the move will protect jobs lost to the COVID-19) pandemic. The New York Times reported it is not clear what authority he has to shut down immigration. The move adds to other efforts the administration has made against immigration since he took office, including expanding trvel restrictions from certain countries, delaying visa processing, and barring asylum seekers and undocumented immigrants from entering the country, The Associated Press noted.
According to health officials in Los Angeles, California, where antibody testing was conducted on residents, nearly 4.1% of adults tested positive for novel coronavirus antibodies, indicating that the rate of infection may be 40 times higher than the number of confirmed cases, Reuters reported. The serology tests were conducted by researchers from the University of Southern California on 863 people. Results indicate that the death rate may be lower than believed, but it may also suggest the virus is more easily spread, even by people who show no symptoms.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More